ReviewPsychopharmacology2013
Spicing things up: synthetic cannabinoids.
Review in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed.
- The Synthetic Cannabinoid AKB-48 Induces Cell Death in Murine Cerebellum Through Different Signaling Pathways.International journal of molecular sciences · 2026Article
- Behavioral pharmacology of novel synthetic indazole, indole, and benzimidazole cannabinoids in rodents.Journal of cannabis research · 2026Article
- Detection of drugs of abuse: evolving analytical strategies and emerging challenges.Frontiers in chemistry · 2026Review
- Long-Lasting Cognitive and Physical Impairment After Recreational Use of the Semisynthetic Cannabinoid Hexahydrocannabinonyl (HHC-C9): A Case Report.Reports (MDPI) · 2025Article
- Review
- Identification of non-glandular trichome hairs in cannabis using vision-based deep learning methods.Journal of forensic sciences · 2025Article
- Comparison between pediatric and adult acute natural cannabinoids toxicity: A 5-year retrospective study with special consideration of acute synthetic cannabinoids toxicity.Toxicology reports · 2025Article
- Long-term consequences of adolescent exposure to the synthetic cannabinoid AB-FUBINACA in male and female mice.iScience · 2025Article
- Involvement of CB1R and CB2R Ligands in Sleep Disorders and Addictive Behaviors in the Last 25 Years.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Safety assessment of female sexual hygiene product containing cannabidiol in new zealand white rabbit and clinical trial.Toxicology reports · 2024Article
- Cardiac effects of 5F-Cumyl-PEGACLONE.International journal of legal medicine · 2024Article
- The synthetic cannabinoids menace: a review of health risks and toxicity.European journal of medical research · 2024Review
- Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy.Biomolecules · 2023Review
- Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review.Brain sciences · 2023Review
- Behavioral, biochemical and histopathological toxic profiles induced by sub-chronic cannabimimetic WIN55, 212-2 administration in mice.BMC pharmacology & toxicology · 2023Article
- The Old and the New: Cardiovascular and Respiratory Alterations Induced by Acute JWH-018 Administration Compared to ΔInternational journal of molecular sciences · 2023Article
- Aberrant salience in cannabis-induced psychosis: a comparative study.Frontiers in psychiatry · 2023Article
- Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers.Biomedicines · 2022Review
- A GPCR-based yeast biosensor for biomedical, biotechnological, and point-of-use cannabinoid determination.Nature communications · 2022Article
- Novel Psychoactive Substances: The Razor's Edge between Therapeutical Potential and Psychoactive Recreational Misuse.Medicines (Basel, Switzerland) · 2022Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
rationaleRecently, products containing synthetic cannabinoids, collectively referred to as Spice, are increasingly being used recreationally.
objectivesThe availability, acute subjective effects-including self-reports posted on Erowid-laboratory detection, addictive potential, and regulatory challenges of the Spice phenomenon are reviewed.
resultsSpice is sold under the guise of potpourri or incense. Unlike delta-9-tetrahydrocannabinol, the synthetic cannabinoids present in Spice are high-potency, high-efficacy, cannabinoid receptor full agonists. Since standard urine toxicology does not test for the synthetic cannabinoids in Spice, it is often used by those who want to avoid detection of drug use. These compounds have not yet been subjected to rigorous testing in humans. Acute psychoactive effects include changes in mood, anxiety, perception, thinking, memory, and attention. Adverse effects include anxiety, agitation, panic, dysphoria, psychosis, and bizarre behavior. Psychosis outcomes associated with Spice provide additional data linking cannabinoids and psychosis. Adverse events necessitating intervention by Poison Control Centers, law enforcement, emergency responders, and hospitals are increasing. Despite statutes prohibiting the manufacture, distribution, and sale of Spice products, manufacturers are replacing banned compounds with newer synthetic cannabinoids that are not banned.
conclusionsThere is an urgent need for better research on the effects of synthetic cannabinoids to help clinicians manage adverse events and to better understand cannabinoid pharmacology in humans. The reported psychosis outcomes associated with synthetic cannabinoids contribute to the ongoing debate on the association between cannabinoids and psychosis. Finally, drug detection tests for synthetic cannabinoids need to become clinically available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.